Research progress in the relationship between plasma FIB and prostate cancer

The incidence of prostate cancer （PCa） has been increased year by year， mainly occurring in elderly men. Currently， prostate-specific antigen （PSA） is still used as a marker for diagnosing PCa in clinical practice. However， the accuracy and sensitivity of PSA remain relatively low. Identifying more clinical detection parameters for assisting diagnosis becomes a research hotspot. Most of patients with malignant tumors are in a hypercoagulable state. Studies have found that plasma fibrinogen （FIB） is differentially expressed in PCa. In addition， FIB has been considered as a potential tumor-promoting factor in PCa. In this article， the discovery， biological structure， physiological function， pathological changes （inflammation and tumor） and functions of plasma FIB， especially the relationship between plasma FIB and PCa， were systematically reviewed， aiming to provide reference for relevant clinical research.